Natalizumab for relapsing-remitting multiple sclerosis
Natalizumab para la esclerosis múltiple remitente-recurrente
Centro de Esclerosis Múltiple de Cataluña, Hospital Universitario Vall d’Hebron, Barcelona, Spain
Read
3824
Timeswas read the article
1094
Total PDF
2730
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 82 | 3 | 85 |
| 2025 11 | 406 | 54 | 460 |
| 2025 10 | 97 | 18 | 115 |
| 2025 9 | 38 | 19 | 57 |
| 2025 8 | 68 | 23 | 91 |
| 2025 7 | 92 | 8 | 100 |
| 2025 6 | 71 | 3 | 74 |
| 2025 5 | 54 | 5 | 59 |
| 2025 4 | 51 | 4 | 55 |
| 2025 3 | 54 | 9 | 63 |
| 2025 2 | 41 | 4 | 45 |
| 2025 1 | 37 | 8 | 45 |
| 2024 12 | 51 | 9 | 60 |
| 2024 11 | 74 | 10 | 84 |
| 2024 10 | 42 | 11 | 53 |
| 2024 9 | 63 | 6 | 69 |
| 2024 8 | 46 | 9 | 55 |
| 2024 7 | 34 | 7 | 41 |
| 2024 6 | 44 | 9 | 53 |
| 2024 5 | 36 | 14 | 50 |
| 2024 4 | 33 | 3 | 36 |
| 2024 3 | 70 | 13 | 83 |
| 2024 2 | 35 | 24 | 59 |
| 2024 1 | 35 | 12 | 47 |
| 2023 12 | 45 | 10 | 55 |
| 2023 11 | 32 | 14 | 46 |
| 2023 10 | 42 | 25 | 67 |
| 2023 9 | 25 | 11 | 36 |
| 2023 8 | 35 | 11 | 46 |
| 2023 7 | 45 | 26 | 71 |
| 2023 6 | 27 | 16 | 43 |
| 2023 5 | 49 | 18 | 67 |
| 2023 4 | 61 | 6 | 67 |
| 2023 3 | 27 | 17 | 44 |
| 2023 2 | 41 | 11 | 52 |
| 2023 1 | 15 | 8 | 23 |
| 2022 12 | 10 | 12 | 22 |
| 2022 11 | 22 | 14 | 36 |
| 2022 10 | 13 | 12 | 25 |
| 2022 9 | 14 | 24 | 38 |
| 2022 8 | 13 | 15 | 28 |
| 2022 7 | 14 | 20 | 34 |
| 2022 6 | 8 | 15 | 23 |
| 2022 5 | 10 | 6 | 16 |
| 2022 4 | 10 | 9 | 19 |
| 2022 3 | 6 | 15 | 21 |
| 2022 2 | 11 | 10 | 21 |
| 2022 1 | 9 | 8 | 17 |
| 2021 12 | 7 | 24 | 31 |
| 2021 11 | 10 | 17 | 27 |
| 2021 10 | 7 | 16 | 23 |
| 2021 9 | 10 | 10 | 20 |
| 2021 8 | 11 | 8 | 19 |
| 2021 7 | 5 | 7 | 12 |
| 2021 6 | 13 | 7 | 20 |
| 2021 5 | 8 | 10 | 18 |
| 2021 4 | 13 | 21 | 34 |
| 2021 3 | 14 | 14 | 28 |
| 2021 2 | 10 | 12 | 22 |
| 2021 1 | 9 | 9 | 18 |
| 2020 12 | 9 | 8 | 17 |
| 2020 11 | 10 | 6 | 16 |
| 2020 10 | 8 | 6 | 14 |
| 2020 9 | 8 | 9 | 17 |
| 2020 8 | 13 | 10 | 23 |
| 2020 7 | 9 | 5 | 14 |
| 2020 6 | 3 | 1 | 4 |
| 2020 5 | 7 | 7 | 14 |
| 2020 4 | 5 | 8 | 13 |
| 2020 3 | 8 | 6 | 14 |
| 2020 2 | 4 | 8 | 12 |
| 2020 1 | 6 | 7 | 13 |
| 2019 12 | 13 | 17 | 30 |
| 2019 11 | 6 | 5 | 11 |
| 2019 10 | 5 | 5 | 10 |
| 2019 9 | 4 | 4 | 8 |
| 2019 8 | 1 | 4 | 5 |
| 2019 7 | 11 | 6 | 17 |
| 2019 6 | 19 | 10 | 29 |
| 2019 5 | 50 | 50 | 100 |
| 2019 4 | 27 | 27 | 54 |
| 2019 3 | 7 | 5 | 12 |
| 2019 2 | 4 | 4 | 8 |
| 2019 1 | 2 | 1 | 3 |
| 2018 12 | 1 | 9 | 10 |
| 2018 11 | 3 | 3 | 6 |
| 2018 10 | 7 | 7 | 14 |
| 2018 9 | 4 | 2 | 6 |
| 2018 8 | 3 | 11 | 14 |
| 2018 7 | 5 | 0 | 5 |
| 2018 6 | 0 | 4 | 4 |
| 2018 5 | 0 | 6 | 6 |
| 2018 4 | 1 | 7 | 8 |
| 2018 3 | 1 | 0 | 1 |
| 2018 2 | 2 | 0 | 2 |
| 2018 1 | 0 | 1 | 1 |
| 2017 12 | 2 | 1 | 3 |
| 2017 11 | 4 | 4 | 8 |
| 2017 10 | 8 | 5 | 13 |
| 2017 9 | 2 | 5 | 7 |
| 2017 8 | 2 | 4 | 6 |
| 2017 7 | 3 | 1 | 4 |
| 2017 6 | 4 | 4 | 8 |
| 2017 5 | 6 | 7 | 13 |
| 2017 4 | 7 | 1 | 8 |
| 2017 3 | 11 | 10 | 21 |
| 2017 2 | 12 | 3 | 15 |
| 2017 1 | 3 | 1 | 4 |
| 2016 12 | 7 | 0 | 7 |
| 2016 11 | 8 | 0 | 8 |
| 2016 10 | 8 | 1 | 9 |
| 2016 9 | 9 | 2 | 11 |
| 2016 8 | 7 | 0 | 7 |
| 2016 7 | 6 | 3 | 9 |
Show all
